|
|
???tair.name??? >
???browser.page.title.author???
|
"li cp"???jsp.browse.items-by-author.description???
Showing items 11-35 of 75 (3 Page(s) Totally)
1 2 3 > >>
View [10|25|50] records per page
| 國家衛生研究院 |
2022-02-19 |
Effect of previous conventional irinotecan treatment in patients with pancreatic cancer being treated with liposomal irinotecan plus 5-fluorouracil and leucovorin
|
Chiu, TJ;Yang, SH;Chiu, SC;Hsueh, SW;Chiang, NJ;Li, CP;Bai, LY;Cheng, FM;Chuang, SC;Shan, YS;Chan, DC;Chen, LT;Yen, CJ;Peng, CM;Su, YY;Chen, YY;Chen, JS;Chou, WC |
| 國家衛生研究院 |
2022-02-01 |
A prospective phase II study of biweekly S-1, leucovorin and gemcitabine in elderly patients with locally advanced or metastatic pancreatic adenocarcinoma
|
Bai, LY;Li, CP;Shan, YS;Chuang, SC;Chen, JS;Chiang, NJ;Chen, YY;Tsou, HH;Chuang, MH;Chiu, CF;Liu, TW;Chen, LT |
| 國家衛生研究院 |
2021-12-17 |
A phase II randomised trial of induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced pancreatic cancer: the Taiwan Cooperative Oncology Group T2212 study
|
Su, YY;Chiu, YF;Li, CP;Yang, SH;Lin, J;Lin, SJ;Chang, PY;Chiang, NJ;Shan, YS;Ch’ang, HJ;Chen, LT |
| 國家衛生研究院 |
2021-11-20 |
Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients’ experience within a population-based study
|
Chiu, TJ;Su, YY;Yang, SH;Li, CP;Bai, LY;Chiang, NJ;Chuang, SC;Shan, YS;Chan, DC;Chen, LT;Yen, CJ;Peng, CM;Chen, YY;Chen, JS;Chou, WC |
| 國家衛生研究院 |
2021-05 |
TCOG T5217 trial: A phase II randomized study of SLOG versus modified FOLFIRINOX as the first-line treatment in locally advanced or metastatic pancreatic ductal adenocarcinoma
|
Chiang, NJ;Shan, YS;Bai, LY;Li, CP;Chen, JS;Yang, SH;Kuo, YC;Chao, Y;Hsieh, YY;Kao, HF;Hsiao, CF;Chen, LT |
| 中山醫學大學 |
2021 |
Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients' experience within a population-based study
|
Chiu, TJ; Su, YY; Yang, SH; Li, CP; Bai, LY; Chiang, NJ; Chuang, SC; Shan, YS; Chan, DC; Chen, LT; Yen, CJ; Peng, CM; Chen, YY; Chen, JS; Chou, WC |
| 國家衛生研究院 |
2020-01 |
Liposomal irinotecan + 5-FU/LV in metastatic pancreatic cancer: Subgroup analyses of patient, tumor, and previous treatment characteristics in the pivotal NAPOLI-1 trial
|
Macarulla Mercade, T;Chen, LT;Li, CP;Siveke, JT;Cunningham, D;Bodoky, G;Blanc, JF;Lee, KH;Dean, A;Belanger, B;Wang-Gillam, A |
| 國家衛生研究院 |
2019-12-17 |
Endothelial-mesenchymal transition harnesses HSP90alpha-secreting M2-macrophages to exacerbate pancreatic ductal adenocarcinoma
|
Fan, CS;Chen, LL;Hsu, TA;Chen, CC;Chua, KV;Li, CP;Huang, TS |
| 國家衛生研究院 |
2019-12-01 |
Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study
|
Bang, YJ;Li, CP;Lee, KH;Chiu, CF;Park, JO;Shan, YS;Kim, JS;Chen, JS;Shim, HJ;Rau, KM;Choi, HJ;Oh, DY;Belanger, B;Chen, LT |
| 國家衛生研究院 |
2018-11-07 |
Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trial
|
Chen, LT;Siveke, JT;Wang-Gillam, A;Li, CP;Bodoky, G;Dean, AP;Shan, YS;Jameson, GS;Macarulla, T;Lee, KH;Cunningham, D;Blanc, JF;Chiu, CF;Schwartsmann, G;Braiteh, FS;Mamlouk, K;Belanger, B;de Jong, FA;Hubner, RA |
| 國家衛生研究院 |
2018-10 |
Randomized, phase III trial comparing adjuvant gemcitabine (Gem) versus Gem plus chemoradiation (CCRT) in curatively resected pancreatic ductal adenocarcinoma (PDAC): A Taiwan cooperative oncology group study
|
Chang, HJ;Chiu, YF;Chen, JS;Li, CP;Ho, CL;Shyr, YM;Chiou, WC;Yeh, CN;Hsieh, RK;Lin, YL;Tien, YW;Hwang, TL;Shan, YS;Chen, LT |
| 國家衛生研究院 |
2018-04-07 |
The clinical impact of the novel tumor marker DR-70 in unresectable gastric cancer patients
|
Hung, YP;Chen, MH;Lin, JS;Hsiao, CF;Shan, YS;Chen, YC;Chen, LT;Liu, TW;Li, CP;Chao, Y |
| 國家衛生研究院 |
2018-02-01 |
Myeloid-derived macrophages and secreted HSP90alpha induce pancreatic ductal adenocarcinoma development
|
Chen, CC;Chen, LL;Li, CP;Hsu, YT;Jiang, SS;Fan, CS;Chua, KV;Huang, SX;Shyr, YM;Chen, LT;Huang, TS |
| 國家衛生研究院 |
2018-02 |
Subgroup analysis by baseline (BL) weight-associated parameters: A phase III study of liposomal irinotecan (nal-IRI)+/--5fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with g
|
Macarulla, TM;Hubner, R;Blanc, JF;Wang-Gillam, A;Li, CP;Bodoky, G;Dean, AP;Yanshen, S;Jameson, GS;Lee, KH;Chiu, CF;Schwartsmann, G;Braiteh, FS;Cunningham, D;Chen, LT;Von Hoff, DD;Mamlouk, KK;de Jong, FA;Siveke, JT |
| 國家衛生研究院 |
2017-11 |
Subgroup analysis by prior non-liposomal irinotecan therapy in NAPOLI-1: A phase 3 study of nal-IRI65-fluorouracil/leucovorin in patients with metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based therapy
|
Blanc, JF;Hubner, R;Li, CP;Wang-Gillam, A;Bodoky, G;Dean, A;Shan, YS;Jameson, G;Mercade, TM;Lee, KH;Cunningham, D;Chiu, CF;Schwartsmann, G;Braiteh, F;von Hoff, D;Chen, LT;Mamlouk, K;de Jong, F;Siveke, J |
| 國家衛生研究院 |
2017-09 |
Prognostic value of baseline neutrophil-to-lymphocyte ratio for predicting clinical outcome in metastatic pancreatic ductal adenocarcinoma (mPDAC) patients treated with liposomal irinotecan (nal-IRI)+5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV alon
|
Hubner, RA;Chen, LT;Li, CP;Bodoky, G;Dean, A;Lee, KH;Cunningham, D;Siveke, JT;Braiteh, FS;de Jong, FA;Belanger, B;Walls, R;Mody, PD;von Hoff, DD;Wang-Gillam, A |
| 國家衛生研究院 |
2017-08 |
A randomized phase II study of gemcitabine plus Z-360, a CCK2 receptor-selective antagonist, in patients with metastatic pancreatic cancer as compared with gemcitabine plus placebo
|
Ueno, M;Li, CP;Ikeda, M;Ishii, H;Mizuno, N;Yamaguchi, T;Ioka, T;Oh, DY;Ichikawa, W;Okusaka, T;Matsuyama, Y;Arai, D;Chen, LT;Park, YS;Furuse, J |
| 國家衛生研究院 |
2017-06-26 |
Subgroup analysis by prior non-liposomal irinotecan therapy in NAPOLI-1: A phase 3 study of nal-IRI +/- 5-fluorouracil/leucovorin in patients with metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based therapy
|
Jean-Frederic, B;Richard, H;Li, CP;Andrea, WG;Gyorgy, B;Andrew, D;Shan, YS;Gayle, J;Teresa, M;Lee, H;David, C;Chiu, CF;Gilberto, S;Fadi, B;Daniel, V;Chen, LT;Khalid, M;Parul, B;Floris, D;Jens, S |
| 國家衛生研究院 |
2017-05 |
The prognostic value of baseline neutrophilto-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) for predicting clinical outcome in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan (nal-IRI; MM
|
Wang-Gillam, A;Chen, LT;Li, CP;Bodoky, G;Dean, A;Lee, KH;Cunningham, D;Hubner, R;Braiteh, FS;Pipas, JM;Belanger, B;de Jong, FA;Mody, PD;Von Hoff, DD;Siveke, JT |
| 國家衛生研究院 |
2017-02 |
Characteristics of long-term survivors in a randomized phase III trial (NAPOLI-1) of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan (nal-IRI; MM-398)+5-FU/LV
|
Wang-Gillam, A;Li, CP;Bodoky, G;Dean, A;Lee, KH;Cunningham, D;Hubner, R;Siveke, JT;Braiteh, FS;Pipas, JM;Belanger, B;de Jong, F;Mody, PD;Chen, LT;Von Hoff, DD |
| 國家衛生研究院 |
2016-12 |
Efficacy and safety of nanoliposomal irinotecan (nal-IRI, MM-398, PEP02, BAX-2398) in patients with metastatic pancreatic cancer in Asia: A subgroup analysis of the phase 3 NAPOLI-1 Study
|
Chen, LT;Li, CP;Chiu, CF;Shan, YS;Park, JO;Chen, JS;Kim, JS;Rau, KM;de Jong, F;Pipas, M;Belanger, B;Wang, E;Lee, KH;Bang, YJ |
| 國家衛生研究院 |
2016-10 |
Final results of NAPOLI-1: A phase 3 study of nal-IRI (MM-398) +/- 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy
|
Chen, LT;Wang-Gillam, A;Li, CP;Bodoky, G;Dean, A;Shan, YS;Jameson, GS;Macarulla, T;Lee, KH;Cunningham, D;Blanc, JF;Hubner, R;Chiu, CF;Schwartsmann, G;Braiteh, F;Belanger, B;Bayever, E;de Jong, F;von Hoff, DD;Siveke, JT |
| 國家衛生研究院 |
2016-10 |
Time course of selected treatment emergent adverse events (TEAEs) in NAPOLI-1: A phase 3 study of nal-IRI (MM-398) +/- 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based ther
|
Hubner, RA;Chen, LT;Siveke, JT;Li, CP;Bodoky, G;Dean, A;Shan, YS;Jameson, GS;Macarulla, T;Lee, KH;Cunningham, D;Blanc, JF;Chiu, CF;Schwartsmann, G;Braiteh, F;Mamlouk, K;Belanger, B;de Jong, F;von Hoff, DD;Wang-Gillam, A |
| 國家衛生研究院 |
2016-05 |
Updated overall survival (OS) analysis of NAPOLI-1: Phase 3 study of nanoliposomal irinotecan (nal-IRI, MM-398), with or without 5-fluorouracil and leucovorin (5-FU/LV), vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine
|
Wang-Gillam, A;Li, CP;Bodoky, G;Dean, A;Shan, YS;Jameson, GS;Macarulla, T;Lee, KH;Cunningham, D;Blanc, JF;Hubner, R;Chiu, CF;Schwartsmann, G;Siveke, JT;Braiteh, FS;Moyo, VM;Belanger, B;Bayever, E;Von Hoff, DD;Chen, LT |
| 國家衛生研究院 |
2016-02 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): A global, randomised, open-label, phase 3 trial
|
Wang-Gillam, A;Li, CP;Bodoky, G;Dean, A;Shan, YS;Jameson, G;Macarulla, T;Lee, KH;Cunningham, D;Blanc, JF;Hubner, RA;Chiu, CF;Schwartsmann, G;Siveke, JT;Braiteh, F;Moyo, V;Belanger, B;Dhindsa, N;Bayever, E;Von Hoff, DD;Chen, LT;the NAPOLI-1 Study Group. |
Showing items 11-35 of 75 (3 Page(s) Totally)
1 2 3 > >>
View [10|25|50] records per page
|
